PRODUCT LITERATURE

DLBS3233 extract, a novel insulin sensitizer with negligible risk of hypoglycemia: A phase-I study

---

DLBS3233 is a standardized extract combination of two Indonesian herbals (Lagerstroemia speciosa L. and Cinnamomum burmanii L.) developed by a patented extraction-technology. DLBS3233 has been proven pre-clinically to have a glucose lowering activity. This Phase 1 clinical study evaluated the safety of DLBS3233 in comparison with the negative-control and pioglitazone 30 mg (active control) in healthy volunteers. In this randomized, open-labeled, Latin-square-designed clinical study consisting of 7 groups of treatment, DLBS3233 capsules were given at doses of 50, 100, 200, 300, 400 mg in each group, respectively.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

TEXTBOOK

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Inlacin

Specific Detail Info

Int J Diabetes & Metab (2012) 21:13-20

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment